WAM
ALXN

Wealthspire Advisors (Maryland)’s Alexion Pharmaceuticals ALXN Stock Holding History

Wealthspire Advisors (Maryland)’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-527
Closed -$71K – 2339
2019
Q1 		$71K Buy
527
+60
+13% +$7.46K 0.01% 768
2018
Q4 		$45K Sell
467
-254
-35% -$30K ﹤0.01% 906
2018
Q3 		$100K Buy
721
+16
+2% +$2.01K 0.01% 688
2018
Q2 		$88K Buy
705
+57
+9% +$6.66K 0.01% 756
2018
Q1 		$72K Sell
648
-53
-8% -$6.33K 0.01% 843
2017
Q4 		$84K Buy
701
+19
+3% +$2.31K 0.01% 784
2017
Q3 		$96K Buy
682
+29
+4% +$3.94K 0.01% 729
2017
Q2 		$79K Buy
653
+104
+19% +$12.1K 0.01% 790
2017
Q1 		$67K Sell
549
-327
-37% -$42.2K 0.01% 721
2016
Q4 		$107K Buy
876
+132
+18% +$16.2K 0.02% 557
2016
Q3 		$91K Sell
744
-15
-2% -$1.93K 0.01% 596
2016
Q2 		$89K Buy
759
+11
+1% +$1.56K 0.01% 554
2016
Q1 		$104K Buy
748
+25
+3% +$3.67K 0.02% 514
2015
Q4 		$138K Buy
+723
New +$126K 0.03% 455

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Wealthspire Advisors (Maryland)'s ALXN Position: Q2 2019 in Review

Wealthspire Advisors (Maryland) sold out of Alexion Pharmaceuticals (ALXN) in Q2 2019, closing a stake of 527 shares — an estimated $71K sold.

Wealthspire Advisors (Maryland) first reported a position in ALXN in Q4 2015 and held it in 14 quarters. The position peaked at $138K in Q4 2015. 636 funds tracked by Wall St. Rank hold ALXN as of Q2 2019.

  • Wealthspire Advisors (Maryland) reported no remaining Alexion Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
  • Wealthspire Advisors (Maryland) sold 527 Alexion Pharmaceuticals shares in Q2 2019, an estimated $71K.
  • Wealthspire Advisors (Maryland) first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 14 quarters.
  • Wealthspire Advisors (Maryland)'s Alexion Pharmaceuticals position peaked at $138K in Q4 2015.
  • 636 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2019.

Based on Wealthspire Advisors (Maryland)'s 13F filing for Q2 2019, filed 12 Aug 2019.